Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Employees

Sector

Pharmaceuticals

Calendar

13/05 - Q1 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
17/26/17	4.410 $	-0.45%	42,730
13/26/13	4.430 $	-3.49%	25,758
12/26/12	4.590 $	-0.65%	23,199
11/26/11	4.620 $	-1.28%	29,511
10/26/10	4.680 $	+2.18%	41,823

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.410USD

Average target price

12.25USD

Spread / Average Target

+177.78%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 02:30:00 18/02/2026 am IST			5-day change	1st Jan Change
4.410 ^USD	-0.45%		-5.77%	+1.61%

11/02	PolyPid Ltd., Q4 2025 Earnings Call, Feb 11, 2026
11/02	PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

Capitalization	8.03Cr 6.79Cr 6.2Cr 5.93Cr 11Cr 727.69Cr 11Cr 72Cr 29Cr 351Cr 30Cr 29Cr 1.23TCr	P/E ratio 2025	-2.08x	P/E ratio 2026 *	-2.99x
Enterprise value	8.03Cr 6.79Cr 6.2Cr 5.93Cr 11Cr 727.69Cr 11Cr 72Cr 29Cr 351Cr 30Cr 29Cr 1.23TCr	EV / Sales 2025	-	EV / Sales 2026 *	-
Free-Float	16.06%	Yield 2025 *	-	Yield 2026 *	-

11/02	PolyPid Ltd., Q4 2025 Earnings Call, Feb 11, 2026
11/02	PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
16/12	Polypid names medtech veteran Brooke Story as board chairman	RE
16/12	PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors, Effective December 11, 2025	CI
11/12	PolyPid Ltd. - Special Call
03/12	PolyPid Ltd. Announces Positive Fda Pre-Nda Meeting Minutes for D-Plex100 Supporting Nda Submission	CI
03/12	Polypid announces positive FDA Pre-NDA meeting minutes	RE
12/11	PolyPid Ltd., Q3 2025 Earnings Call, Nov 12, 2025
12/11	PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/11	Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln	RE
01/25/01	Polypid Ltd. to Present Its Positive Phase 3 Shield II Topline Results At the 2025 American College of Surgeons Clinical Congress	CI
16/25/16	PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection	CI
16/25/16	Polypid clears Israeli health ministry GMP inspection, nears commercial manufacturing for D-PLEX	RE

18/25/18	Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating	MT
05/25/05	Roth Capital Initiates PolyPid at Buy With $9 Price Target	MT
27/24/27	HC Wainwright Adjusts Price Target on PolyPid to $11 From $14, Keeps Buy Rating	MT
12/23/12	HC Wainwright Initiates PolyPid With Buy Rating, Price Target is $16	MT
07/22/07	Barclays Downgrades PolyPid to Equalweight From Overweight, Adjusts Price Target to $2.50 From $22	MT

PolyPid Ltd. Share Price

Equities

PYPD

IL0011326795

Pharmaceuticals

Valuation: PolyPid Ltd.

Chart: PolyPid Ltd.

Latest news: PolyPid Ltd.

Last Transcript: PolyPid Ltd.

Analysts' recommendations: PolyPid Ltd.

Press Releases: PolyPid Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: PolyPid Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

11/02	PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results	AQ
28/01	PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026	AQ
16/12	PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors	AQ
03/12	PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission	AQ
25/11	PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025	AQ

1 day	-0.45%
1 week	-5.77%
Current month	-3.71%
1 month	+0.92%
3 months	+21.32%
6 months	+27.83%
Current year	+1.61%

1 week	4.22	4.62
1 month	4.22	5.12
Current year	4.22	5.12
1 year	2.3	5.12
3 years	2.3	22.8
5 years	2.3	437.18
10 years	2.3	583.5

Manager	Title	Age	Since
Dikla Akselbrad CEO	Chief Executive Officer	52	01/07/2022
Jonny Missulawin DFI	Director of Finance/CFO	39	-
Ori Warshavsky COO	Chief Operating Officer	48	01/01/2022

Director	Title	Age	Since
Robert Stein BRD	Director/Board Member	75	01/06/2020
Itzhak Krinsky BRD	Director/Board Member	73	01/12/2018
Yechezkel Barenholz BRD	Director/Board Member	83	01/04/2008

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
POLYPID LTD.	-0.45%	-5.77%	+49.49%	-79.86%	8.06Cr
ELI LILLY AND COMPANY	-0.38%	+1.08%	+22.72%	+215.48%	93TCr
JOHNSON & JOHNSON	-0.05%	+2.09%	+55.83%	+51.71%	59TCr
ABBVIE INC.	+0.59%	+4.68%	+20.73%	+53.90%	41TCr
ROCHE HOLDING AG	+2.16%	+5.16%	+25.45%	+32.23%	38TCr
ASTRAZENECA PLC	+2.39%	+9.59%	+32.51%	+35.14%	32TCr
NOVARTIS AG	+1.52%	+6.10%	+34.09%	+59.90%	31TCr
MERCK & CO., INC.	+0.13%	+3.77%	+46.45%	+11.00%	30TCr
NOVO NORDISK A/S	+0.73%	-1.60%	-45.57%	-37.14%	22TCr
AMGEN INC.	+1.13%	+2.39%	+28.23%	+55.22%	20TCr
Average	+0.78%	+2.30%	+26.99%	+39.76%	36.52TCr
Weighted average by Cap.	+0.64%	+2.57%	+28.13%	+82.42%

	2025	2026 *
Net sales	-	-
Net income	-3.25Cr -2.74Cr -2.51Cr -2.4Cr -4.43Cr -294.15Cr -4.59Cr -29Cr -12Cr -141.88Cr -12Cr -12Cr -498.48Cr	-3.59Cr -3.04Cr -2.77Cr -2.66Cr -4.91Cr -325.6Cr -5.09Cr -32Cr -13Cr -157.05Cr -13Cr -13Cr -551.77Cr
Net Debt	-	-